ONWARD Medical

ONWARD Medical

Verified
Developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injuries. Learn more

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$192m (Public information from Jul 2024)
Company register number 64598748
Eindhoven Noord-Brabant (HQ), Lausanne Canton of Vaud (founding location)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2019202020212022202320242025
Revenues-----5.0m11.7m
% growth------136 %
EBITDA(10.5m)(15.3m)(28.3m)(31.3m)(34.0m)(34.0m)(46.0m)
% EBITDA margin-----(687 %)(394 %)
Profit(13.5m)(20.0m)(34.3m)(32.8m)(36.2m)(35.3m)(42.5m)
% profit margin-----(714 %)(364 %)
EV / revenue-----35.0x18.7x
EV / EBITDA---10.9x-6.0x-4.5x-5.1x-4.8x
R&D budget5.4m5.8m7.9m13.1m13.8m--
  • Edit
DateInvestorsAmountRound
-

N/A

-

€30.0m

Early VC
N/A

CHF93.0m

Valuation: CHF420m

-22.9x EV/LTM EBITDA

IPO
*

€1.2m

Grant
*
N/A

€20.0m

Private Placement VC
*

€52.2m

Post IPO Debt
Total Funding$86.3m

Recent News about ONWARD Medical

Edit
More about ONWARD Medicalinfo icon
Edit

ONWARD is a pioneering startup that operates in the medical technology sector, specifically focusing on spinal cord injury therapies. The company is comprised of a multidisciplinary team of scientists, engineers, and physicians, all united by a common goal: to develop innovative therapies that can significantly improve the lives of people living with spinal cord injuries.

ONWARD's flagship product is the ARC Therapy, a groundbreaking technology that uses targeted, programmed stimulation of the spinal cord to restore movement in individuals with spinal cord injuries. This investigational device, which is not yet available for commercial use, has shown potential benefits beyond restoring movement, including improved bladder control, sexual function, and blood pressure regulation.

The company's business model is based on the development and eventual commercialization of its proprietary ARC Therapy. It generates revenue through the licensing of its intellectual property, developed in partnership with leading global neuroscience research institutions such as the Swiss Federal Institute of Technology, Lausanne University Hospital, the University of Louisville, and Caltech.

ONWARD's target market includes individuals with spinal cord injuries, as well as healthcare providers and institutions that treat these patients. The company's long-term financial prospects are promising, given the significant unmet need for effective therapies in this area and the potential for its technology to revolutionize the treatment of spinal cord injuries.

Keywords: Medical Technology, Spinal Cord Injury, ARC Therapy, Intellectual Property, Licensing, Healthcare Providers, Neuroscience Research, Treatment Revolution, Neuroprosthesis, Locomotor Deficits.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.